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Recommended Childhood Immunization Schedule —
United States, 1995
Summary
The need for a single childhood immunization schedule prompted the unifica-
tion of previous vaccine recommendations made by the American Academy of
Pediatrics (AAP) and the Advisory Committee on Immunization Practices (ACIP).
In addition to presenting the newly recommended schedule for the administra-
tion of vaccines during childhood, this report addresses the previous differences
between the AAP and ACIP childhood vaccination schedules and the rationale
for changing previous recommendations.
INTRODUCTION
Since 1988, the U.S. childhood immunization schedule has rapidly expanded to ac-
commodate the introduction of new, universally recommended vaccines (i.e.,
Haemophilus influenzae type b [Hib] conjugate [1,2 ] and hepatitis B [2,3 ] vaccines)
and recommendations for a second dose of measles-mumps-rubella vaccine (MMR)
(4,5 ) and the use of acellular pertussis vaccines (2,6 ). For approximately 30 years, the
Advisory Committee on Immunization Practices (ACIP) and the Committee on Infec-
tious Diseases (COID) of the American Academy of Pediatrics (AAP)—the two groups
responsible for developing vaccine recommendations for the public and private sec-
tors—worked to develop similar schedules for routine childhood vaccination.
However, some differences in the two schedules persisted. The unification of these
childhood immunization schedules is essential to issuing consistent recommenda-
tions for both private and public health practitioners and for parents.
In February 1994, a working group was convened comprising members of AAP,
ACIP, the American Academy of Family Physicians (AAFP), the Food and Drug Admini-
stration (FDA), the National Institutes of Health, and CDC. Representatives from state
immunization programs, the Maternal and Child Health Bureau of the Health Re-
sources and Services Administration, and vaccine manufacturers also participated.
The objective of this working group was to develop a single, scientifically valid child-
hood immunization schedule—presented in an easily comprehensible format—that
would accommodate the current recommendations of both ACIP and AAP and ensure
the timely vaccination of preschool-age children. The schedule would identify a speci-
fied age for administering each vaccine dose and provide an acceptable range of ages
to ensure flexibility for health-care providers. The working group also addressed the
number of antigens and injections that should be administered at each visit, the num-
ber of visits required for children by 2 years of age, the availability of combined
diphtheria and tetanus toxoids and pertussis (DTP)-Hib vaccines, and the capacity of
the schedule to accommodate newly licensed vaccines (e.g., varicella vaccine). This
report presents the recommended childhood immunization schedule (approved by
ACIP, AAP, and AAFP) (Table 1) and the rationale for changing the previous recommen-
dations. Practitioners should consult the Report of the Committee on Infectious
Diseases (Red Book) (2 ), the vaccine-specific recommendations of ACIP, and the
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 *Recommended vaccines are listed under the routinely recommended ages. Shaded bars
indicate range of acceptable ages for vaccination. 
†Although no changes have been made to this schedule since publication in MMWR (weekly)
in January 1995, this table has been revised to more accurately reflect the recommendations.
§Vaccines recommended for administration at 12–15 months of age may be administered at
either one or two visits.
¶Infants born to hepatitis B surface antigen (HBsAg)-negative mothers should receive the
second dose of hepatitis B vaccine between 1 and 4 months of age, provided at least
1 month has elapsed since receipt of the first dose. The third dose is recommended between
6 and 18 months of age. Infants born to HBsAg-positive mothers should receive
immunoprophylaxis for hepatitis B with 0.5 mL Hepatitis B Immune Globulin (HBIG) within
12 hours of birth, and 5 µg of either Merck, Sharpe, & Dohme (West Point, Pennsylvania)
vaccine (Recombivax HB®)  or  10  µg of SmithKline Beecham (Philadelphia) vaccine
(Engerix-B®) at a separate site. For these infants, the second dose of vaccine is
recommended at 1 month of age and the third dose at 6 months of age. All pregnant women
should be screened for HBsAg during an early prenatal visit.
**The fourth dose of DTP may be administered as early as 12 months of age, provided at
least 6 months have elapsed since the third dose of DTP. Combined DTP-Hib products may
be used when these two vaccines are administered simultaneously. Diphtheria and tetanus
toxoids and acellular pertussis vaccine (DTaP) is licensed for use for the fourth and/or fifth
dose of DTP in children ≥15 months of age and may be preferred for these doses in children
in this age group.
††
Three H. influenzae  type b conjugate vaccines are available for use in infants:
a) oligosaccharide conjugate Hib vaccine (HbOC) (HibTITER®, manufactured by Praxis
Biologics, Inc. [West Henrietta, New York] and distributed by Lederle-Praxis Biologicals
[Wayne, New Jersey]); b) polyribosylribitol phosphate-tetanus toxoid conjugate (PRP-T)
(ActHIBTM, manufactured by Pasteur Mérieux Sérums & Vaccins, S.A. [Lyon, France] and
distributed by Connaught Laboratories, Inc. [Swiftwater, Pennsylvania], and OmniHIBTM,
manufactured by Pasteur Mérieux Sérums & Vaccins, S.A. and distributed by SmithKline
Beecham); and c) Haemophilus  b conjugate vaccine (Meningococcal Protein Conjugate)
(PRP-OMP) (PedvaxHIB®, manufactured by Merck, Sharp, & Dohme). Children who have
received PRP-OMP at 2 and 4 months of age do not require a dose at 6 months of age.
After the primary infant Hib conjugate vaccine series is completed, any licensed Hib
conjugate vaccine may be administered as a booster dose at age 12–15 months.
§§The second dose of MMR vaccine should be administered EITHER at 4–6 years of age OR
at 11–12 years of age. 
Source: Advisory Committee on Immunization Practices, American Academy of Pediatrics, and


















































TABLE 1. Recommended childhood immunization schedule*† — United States,
January 1995
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official manufacturers’ package inserts or the Physician’s Desk Reference (PDR) (7 ) for
detailed information and specific recommendations for administration of vaccines.
RATIONALE FOR CHANGE AND CURRENT
RECOMMENDATIONS
In 1994, the substantial differences between the recommended AAP and ACIP
schedules included the schedule for infant hepatitis B vaccination and the timing of
the third dose of oral poliovirus vaccine (OPV) and the second dose of MMR (Table 2).
Resolution of the differences between the schedules is described in the following
sections.
OPV
Since 1963, OPV has been the recommended vaccine for inducing long-lasting im-
munity to poliomyelitis. The primary series has consisted of two doses administered
during infancy at approximately 2-month intervals beginning at 6–8 weeks of age, a
third dose recommended at 6 weeks to 14 months after the second dose (generally
administered at 15–18 months of age), and a fourth dose administered at 4–6 years of
age. In late 1993, ACIP recommended that the third dose of OPV be administered at 6
months of age (8 ), whereas AAP recommended that this dose be administered at 6–18
months of age (2 ).
A study comparing two infant immunization schedules (one recommending vacci-
nation at approximately 2, 4, 6, and 12 months of age and one at 2, 4, and 12 months
of age) indicated high seroconversion rates (i.e., 96%–100%) and similar geometric
mean antibody titers (measured after three doses) when following either schedule (9).
Several other studies have evaluated the seroresponse to OPV administered at 2, 4,
and 6 months; 2, 4, and 12 months; and 2, 4, and 18 months of age (10–13 ). These data
indicated excellent response to all serotypes of OPV when the third dose was admin-
istered at 6, 12, or 18 months of age (Table 3).
Recommendation: Because immune response is not affected by adminis-
tering the third dose of OPV at as early as 6 months of age, and because
earlier scheduling can ensure a higher rate of completion of the OPV pri-
mary series at a younger age, the third dose of OPV should be
administered routinely at 6 months of age. Vaccination at as late as 18
months of age remains an acceptable alternative.
TABLE 2. Differences between the American Academy of Pediatrics’ (AAP) and the
Advisory Committee on Immunization Practices’ (ACIP) childhood immunization
schedules, by selected vaccine — United States, 1994
Vaccine or vaccine dose AAP recommendation ACIP recommendation
OPV-3* 6–18 mos 6 mos
Hepatitis B 0–2, 1–4,† 6–18 mos Birth, 1–2, 6–18 mos OR
2, 4, 6–18 mos
MMR-2§ 11–12 yrs 4–6 yrs
*The third dose of oral poliovirus vaccine.
†Provided that at least 1 month has elapsed between the first and second doses.
§The second dose of measles-mumps-rubella vaccine.
Vol. 44 / No. RR-5 MMWR 3
MMR
First Dose
During 1989 and 1990, more than 55,000 cases of measles were reported in the
United States. Nearly 25% of these cases occurred among children ≤15 months of age,
including approximately 9% among children 12–15 months of age (CDC, unpublished
data). At that time, the recommended age for routine measles vaccination was 15
months of age. Recent studies have examined the impact of vaccine-induced immu-
nity on maternally derived transplacental antibody levels; these studies have indicated
that younger women (i.e., women who were born after 1956 and who are therefore
more likely to have vaccine-induced immunity) transfer lower titers of measles anti-
bodies to their newborn infants than older women (who are more likely to have had
natural measles infection). The transplacental antibody acquired by these younger
mothers’ infants wanes earlier, causing their children to become susceptible to mea-
sles at a younger age (14,15 ). This finding suggests that children born to younger
mothers might respond well to measles vaccine administered at 12 months of age. In
one recent study in which children randomly received measles vaccine at either 12 or
15 months of age (16 ), the measles antibody response to MMR was 93% when the
vaccine was administered at 12 months of age; at 15 months of age, the antibody
response was 98%. Among children of mothers born after 1961, who probably had
received measles vaccine and were less likely to have had measles infection than
women born in previous years, the seroconversion rate was 96% among children vac-
cinated at 12 months of age and 98% among those vaccinated at 15 months of age.
Recommendation: The slightly lower response to the first dose of measles
vaccine when administered at 12 months of age compared with admini-
stration at 15 months of age has limited clinical importance because a
second dose of MMR is recommended routinely for all children, enhancing
the likelihood of seroconversion among children who do not respond to
the first dose. In addition, earlier scheduling of the first dose of measles
vaccine can improve vaccination coverage. In 1994, both AAP and ACIP
recommended administration of the first dose of MMR vaccine at 12–15
months of age (2,8 ); this schedule is still recommended.
TABLE 3. Percentage of children with serum-neutralizing antibody to poliovirus types





After two doses (%) After three doses (%)
p1 p2 p3 p1 p2 p3
2, 4, 6 Hardy (9 ) 93 100 91 97 100  96
Cohen-Abbo (10 ) 89 100 93 99 100  99
2, 4, 12 Hardy (9 ) 92  99 90 96 100  96
Faden (11 ) 100 100 100 100 100 100
2, 4, 18 McBean (12 ) 92 100 96 97 100 100
Modlin (13 ) 95 100 90 95 100 100
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Second Dose
In 1989, both ACIP and AAP recommended that all children receive a second dose
of measles-containing vaccine; however, ACIP recommended administering the sec-
ond dose at 4–6 years of age (5 ), and AAP recommended this dose at 11–12 years of
age (4 ). Most states have implemented school entry requirements based on one or
both of these recommendations. Currently, 12 states require administration of the sec-
ond dose of measles vaccine before children enter kindergarten (i.e., at 4–6 years of
age), 12 require this dose before entry to middle school (i.e., at 11–12 years of age),
and 13 states require that the second dose be administered before children enter
either kindergarten or middle school.
Recommendation: Because response to the second dose is high when ad-
ministered to children in either age group (CDC, unpublished data), and
because state-specific laws govern the administration of the second dose
of MMR, the second dose of MMR can be administered at either 4–6 years
of age or 11–12 years of age.
Hepatitis B
Universal hepatitis B vaccination of infants was recommended in 1991 (3,17 ). Al-
though a protective serologic response (i.e., ≥10 mIU/mL) has been demonstrated in
>95% of hepatitis B vaccine recipients who received vaccine according to several
schedules beginning at birth or 2 months of age (Table 4), higher antibody titers were
achieved when the third dose was administered at 12 or 15 months of age (18,19 ).
Available data indicate that higher titers of antibody ensure longer persistence of an-
tibody (20–22 ); however, the effect of high antibody levels on long-term protection
against disease is not known.
TABLE 4. Percentage of children who seroconverted and geometric mean titers (GMTs)
after vaccination with hepatitis B vaccine, by age at first dose and vaccination schedule

















0, 1, 2, 12 62  9 3  95  110
46 13 4 100  647
0, 1, 6 78  9 3  96  262
0, 2, 4 49  9 3  98   99
0, 2, 6 50  9 3  98  216
2 mos
2, 4, 6 82  7 3  98  202
2, 4, 6, 15§ 32 14 4 100 1,793 
2, 4, 12 41 11 3 100 1,633 
2, 4, 12 (18 ) 52 11 3  98 1,358 
2, 4, 15 38 14 3  97 1,527 
2, 4, 15 (18 ) 50 14 3 100 3,424 
*At the time of measurement.
†Children who had ≥10 mIU/mL of antibody to hepatitis B surface antigen.
§A subset of the infants vaccinated at 2, 4, and 6 months of age.
Source: David West, Merck Research Laboratories.
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Recommendation: The routine hepatitis B vaccination series should begin
at birth, with the second dose administered at 2 months of age, for infants
whose mothers are hepatitis B surface antigen (HBsAg) negative. Accept-
able ranges are from birth through 2 months of age for the first dose and
from 1 through 4 months of age for the second dose, provided that at least
1 month elapses between these doses. The third dose should be adminis-
tered at 6–18 months of age. Limited available data suggest an augmented
response when the third dose is administered after 12 months of age
(Merck Research Laboratories, unpublished data, 1994). Infants of HBsAg-
positive mothers should receive the first dose of vaccine at birth (along
with immunoprophylaxis with hepatitis B immune globulin); the second
dose at 1 month of age; and the third dose at 6 months of age.
Diphtheria and Tetanus Toxoids and Pertussis Vaccine (DTP)
Since the late 1940s, the approved schedule for DTP has consisted of a primary
series of three doses administered at 4–8 week intervals and a fourth (i.e., reinforcing)
dose administered 6–12 months after the third dose. Although the fourth dose has
been administered routinely at 15–18 months of age, it may be administered as early
as 12 months of age, provided that at least 6 months elapse between the third and
fourth dose. No recent data are available comparing the immunogenicity of DTP or
diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) when adminis-
tered at 12–14 months with immunogenicity at 15–18 months of age when vaccine is
either administered alone or simultaneously with MMR and Hib vaccines.
Recommendation: The current schedule for DTP vaccination is still recom-
mended—including the option that the fourth dose may be administered
at as early as 12 months of age if 6 months elapse after the third dose.
Thus, the fourth dose of DTP can be scheduled with other vaccines that are
administered at 12–18 months of age. DTaP currently is licensed for use
only as the fourth and/or fifth dose of the DTP series for children ≥15
months of age (2,6 ).
Tetanus and Diphtheria Toxoids, Adsorbed,
For Adult Use (Td)
For most persons who received a dose of DTP vaccine at 4–6 years of age, the
first dose of Td is administered at 14–16 years of age and every 10 years thereafter
to maintain adequate protection against tetanus and diphtheria (6 ). A recent U.S.
serologic survey of tetanus immunity (23 ) indicated that tetanus immunity in the ma-
jority of the population decreases with time after the administration of the recipient’s
most recent vaccination. Among persons 6–16 years of age who had received their
most recent tetanus vaccination 6–10 years previously, 28% had tetanus antibody tit-
ers lower than protective levels, which suggested that Td could be administered as
early as 11–12 years of age.
Recommendation: The booster dose of Td should be administered at 11–
12 years of age, although vaccination at 14–16 years of age is an
acceptable alternative. The earlier scheduling of this dose at 11–12 years of
6 MMWR June 16, 1995
age encourages a routine preadolescent preventive care visit. During this
visit, the practitioner should also administer a second dose of measles-
containing vaccine to those persons who have not already received this
dose and should ensure that children who previously have not received
hepatitis B vaccine begin the vaccination series. Adolescent hepatitis B
vaccination currently is recommended by AAP (2 ); ACIP will issue a simi-
lar recommendation. A routine visit at 11–12 years of age also will facilitate
administration of other needed vaccines to adolescents.
SIMULTANEOUS ADMINISTRATION OF MULTIPLE VACCINES
Simultaneous administration of vaccines has been recommended through the ad-
ministration of combined vaccines (e.g., DTP vaccine, trivalent OPV, and MMR
vaccine) or administration of multiple vaccines at different sites or by different routes
(e.g., simultaneous administration of DTP, OPV, and Hib). Several studies have exam-
ined the safety and immunogenicity of simultaneously administered MMR and Hib
(24,25 ); DTP, OPV, and MMR (26,27 ); DTP, OPV, and Hib (25,28 ); hepatitis B, DTP, and
OPV (29–31 ); and hepatitis B and MMR (Merck Research Laboratories, unpublished
data, 1993). Hepatitis B vaccine, the vaccine most recently licensed for use among
infants, has been shown to be safe and effective when administered from birth
through 15 months of age with other routinely recommended childhood vaccines (D.
Greenberg, personal communication, 1994) (32 ). The available safety and immuno-
genicity data for vaccines currently recommended by ACIP and AAP have been
reviewed recently (33 ). Although data are limited concerning the simultaneous ad-
ministration of the entire recommended vaccine series (i.e., DTP, OPV, MMR, and Hib
vaccines, with or without hepatitis B vaccine), data from numerous studies have indi-
cated no interference between routinely recommended childhood vaccines (either
live, atttenuated or killed) (33 ). These findings support the simultaneous use of all
vaccines as recommended.
CONCLUSION
The development of a unified childhood immunization schedule approved by ACIP,
AAP, and AAFP represents the beginning of a process that will ensure continued col-
laboration among the recommending groups, the pharmaceutical manufacturing
industry, and FDA to maintain and work toward further simplification of a unified
schedule. The recommended childhood immunization schedule will be updated and
published annually.
Since the development of these recommendations in January 1995, FDA has li-
censed varicella zoster virus vaccine for use among susceptible persons ≥12 months
of age. The ACIP will publish recommendations for this new vaccine, and these recom-
mendations will be incorporated into the 1996 Recommended Childhood
Immunization Schedule.
Vol. 44 / No. RR-5 MMWR 7
References
1. ACIP. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b
disease among infants and children two months of age and older: recommendations of the
Immunization Practices Advisory Committee. MMWR 1991;40(No. RR-1):1–7.
2. American Academy of Pediatrics. Active and passive immunization. In: Peter G, ed. 1994 Red
Book: report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American
Academy of Pediatrics, 1994:1–67.
3. ACIP. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United
States through universal childhood vaccination: recommendations of the Immunization Prac-
tices Advisory Committee. MMWR 1991;40(No. RR-13):1–25.
4. American Academy of Pediatrics, Committee on Infectious Diseases. Measles: reassessment
of the current immunization policy. Pediatrics 1989;84:110–1.
5. ACIP. Measles prevention: recommendations of the Immunization Practices Advisory Com-
mittee (ACIP). MMWR 1989;38(No. S-9):1–18.
6. ACIP. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use—sup-
plementary ACIP statement: recommendations of the Advisory Committee on Immunization
Practices. MMWR 1992;41(No. RR-1):1–10.
7. Medical Economics Company. Physician’s desk reference. 49th ed. Montvale, NJ: Medical Eco-
nomics Company Inc, 1995.
8. ACIP. General recommendations on immunization: recommendations of the Advisory Com-
mittee on Immunization Practices (ACIP). MMWR 1994;43(No. RR-1):1–38.
9. Hardy GE, Hopkins CC, Linnemann CC, Hatch MH, Chambers JC, Witte JJ. Trivalent oral
poliovirus vaccine: a comparison of two infant immunization schedules. Pediatrics
1970;45:444–8.
10. Cohen-Abbo A, Culley BS, Reed GW, et al. Seroresponse to trivalent oral poliovirus vaccine
as a function of dosage interval. Pediatr Infect Dis J 1995;4:100–6.
11. Faden H, Modlin JF, Thomas ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation
of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus
vaccines in childhood: systemic and local immune responses. J Infect Dis 1990;162:1291–7.
12. McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio
vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988;128:615–28.
13. Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca P. Serum neutralizing antibody
response to three experimental sequential IPV-OPV immunization schedules [Abstract]. In:
Programs and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Che-
motherapy. New Orleans, LA: ICAAC, 1993.
14. Lennon JL, Black FL. Maternally derived measles immunity in era of vaccine-protected moth-
ers. J Pediatr 1986;108:671–6.
15. Jenks PJ, Caul EO, Roome AP. Maternally derived measles immunity in children of naturally
infected and vaccinated mothers. Epidemiol Infect 1988;101:473–6.
16. King GE, Markowitz LE. A comparison of seroconversion rates to MMR vaccine of children
vaccinated at 9, 12, or 15 months of age [Abstract]. In: Programs and abstracts of the 34th
Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL: ICAAC,
1994.
17. American Academy of Pediatrics, Committee on Infectious Diseases. Universal hepatitis B
immunization. Pediatrics 1992;89:795–800.
18. Keyserling HL, West DJ, Hesley TM, Bosley C, Wiens BL, Calandra GB. Antibody responses
of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve
or fifteen months of age. J Pediatr 1994;125:67–9.
19. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different
vaccination schedules. J Infect Dis 1989;160:766–9.
20. Stevens CE, Toy PT, Taylor PE, Lee T, Yip H. Prospects for control of hepatitis B virus infection:
implications of childhood vaccination and long-term protection. Pediatrics 1992;20(suppl):
170–3.
21. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of
hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989;261:2362–6.
22. Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination.
J Hepatol 1988;6:201–7.
8 MMWR June 16, 1995
23. Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G. A population-based
serological survey of tetanus immunity: implications for U.S. vaccination policy. N Engl J
Med 1995 (in press).
24. Steinhoff MC, Thomas ML, Dannelfelser S, O’Donovan C. Immunogenicity of H. influenzae
type B-CRM197 conjugate vaccine (HbOC) given simultaneously with routine childhood im-
munizations. Pediatr Res 1990;27:184A.
25. Dashefsky B, Wald E, Guerra N, Byers C. Safety, tolerability, and immunogenicity of concurrent
administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein
conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and
oral poliovirus vaccines in 14- to 23-month old infants. Pediatrics 1990;85(suppl):682–9.
26. Deforest A, Long SS, Lischner HW, et al. Simultaneous administration of measles-mumps-
rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines.
Pediatrics 1988;81:237–46.
27. Berger R, Just M. Lack of interference between vaccines [Letter]. Pediatr Infect Dis J 1983;2:172.
28. Booy R, Moxon ER, MacFarlane JA, Mayon-White RT, Slack MPE. Efficacy of Haemophilus
influenzae type B conjugate vaccine in Oxford Region [Letter]. Lancet 1992;340:847.
29. Greenberg DP, Vadheim SM, Marcy SM, Wong V, Margolis H, Ward JI. Safety and immuno-
genicity of two recombinant hepatitis B vaccines given to 5000 infants as part of routine
immunization at 2, 4, and 6 months of age. In: Program and abstracts of the 31st Interscience
Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: ICAAC, 1991.
30. Huang LM, Lee CY, Hsu CY, et al. Effect of monovalent measles and trivalent measles-mumps-
rubella vaccines at various ages and concurrent administration with hepatitis B vaccine. Pediatr
Infect Dis J 1990;9:461–5.
31. Barone P, Mauro L, Leonardi S, et al. Simultaneous administration of HB recombinant vaccine
with diphtheria and tetanus toxoid and oral polio vaccine: a pilot study. Acta Paediatr Jpn
1991;33:455–8.
32. Greenberg DP, Vadheim CM, Marcy SM, et al. Comparative safety and immunogenicity of
two recombinant Hepatitis B (HBV) vaccines given to infants at 2, 4, and 6 months of age
[Abstract]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial
Agents and Chemotherapy. Anaheim, CA: ICAAC, 1992:264.
33. King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public
health policy that is safe and efficacious. Pediatr Infect Dis J 1994;13:394–407.
Vol. 44 / No. RR-5 MMWR 9
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control
and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis
for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to
lists@list.cdc.gov. The body content should read subscribe mmwr-toc. Electronic copy also is available
from CDC’s World-Wide Web server at http://www.cdc.gov/ or from CDC’s file transfer protocol server at
ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing
Office, Washington, DC 20402; telephone (202) 783-3238.
Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments.
The reporting week concludes at close of business on Friday; compiled data on a national basis are officially
released to the public on the following Friday. Address inquiries about the MMWR Series, including material
to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta,
GA 30333; telephone (404) 332-4555.
All material in the MMWR Series is in the public domain and may be used and reprinted without
permission; citation as to source, however, is appreciated.
✩U.S. Government Printing Office: 1995-633-175/05075 Region IV
MMWR
